WEGOVY — INJECTION AND PILL
Wegovy in the UK: injection, pill and the decisions between them
Wegovy is no longer one simple product story. UK adults may encounter a weekly injection, a higher 7.2mg injection route for defined adults with obesity, and a daily tablet with strict administration instructions. This hub keeps those routes separate and understandable.
Written and researched by Matt O’Brien, founder of Shift Some Timber. Evidence reviewed 2026-08-26.
What Wegovy is
Wegovy contains semaglutide, a GLP-1 receptor agonist used with diet and physical activity for weight management in eligible people. It affects appetite regulation and can help people feel fuller and reduce hunger.
The injection and tablet contain the same active ingredient but are not interchangeable DIY formats. Their doses, administration and transition instructions differ and require prescriber oversight.
The weekly injection route
The injection route normally begins at 0.25mg once weekly and increases gradually. The familiar standard maintenance route reaches 2.4mg weekly. A 7.2mg maximum weekly dose has also been authorised for adult patients with obesity only where clinically indicated after the standard route.
The MHRA approved a single-dose 7.2mg pen in April 2026. This higher dose does not apply to every person using Wegovy and should never be improvised from assumptions about dose or product availability.
The daily Wegovy pill
The Wegovy tablet was authorised by the MHRA on 11 June 2026. The starting dose is 1.5mg once daily, increasing through 4mg and 9mg to 25mg, with at least one month at each level.
Administration matters: the tablet should be swallowed whole after fasting for at least eight hours, with a sip of water, followed by at least 30 minutes without food or drink. Eating or drinking earlier can reduce absorption. This routine is an important practical difference from Foundayo.
Results and expectations
Study averages help compare evidence, but the injection and tablet trials used different populations, designs and timeframes. They should not be presented as a direct head-to-head promise.
A useful decision weighs likely benefit against side effects, routine, cost, access, adherence and the person's broader plan. The most impressive percentage is useless if the treatment cannot be used safely or consistently.
Side effects and muscle retention
Common effects include nausea, diarrhoea, constipation and vomiting. A prescriber should explain what to expect, when to seek advice and how follow-up works.
Men losing weight should also think about adequate nutrition, protein and suitable strength activity. Treatment reduces appetite; it does not automatically preserve muscle or build a sustainable routine.
Access and what happens next
The pill is authorised in the UK but MHRA authorisation does not automatically create NHS access. NICE and NHS decisions follow separate processes. Private availability and pricing can change and should always be dated and sourced.
Shift will maintain separate evidence records for the injection and pill so that a change to one route does not silently alter claims about the other.
Frequently asked questions
Is Wegovy available as both an injection and a tablet in the UK?
Yes. Wegovy contains semaglutide and now has authorised weekly injection and daily tablet routes in the UK, with different doses and administration instructions.
Can Wegovy tablets and injections be swapped directly?
No. The formats use different dose schedules and administration rules. Starting, switching or stopping must be managed by an appropriately qualified prescriber.
Does the Wegovy tablet have fasting instructions?
Yes. Current UK instructions require an overnight fast, a small amount of water and a further wait before food, drink or other oral medicines.
Useful next steps
Sources you can inspect
- MHRA — first GLP-1 tablet approved for weight loss
- MHRA — single-dose Wegovy 7.2mg pen
- NICE — overweight and obesity management
Sources support general information, not an individual suitability decision. External organisations remain responsible for their own content.
Who wrote this?
Matt O’Brien owns the research, writing and plain-English interpretation. Matt has first-hand experience of medically supported weight management and has lost 4½ stone, but he is not presented as a doctor or prescriber.